Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93


HIF1/2-exerted control over glycolytic gene expression is not functionally relevant for glycolysis in human leukemic stem/progenitor cells.

Wierenga ATJ, Cunningham A, Erdem A, Lopera NV, Brouwers-Vos AZ, Pruis M, Mulder AB, Günther UL, Martens JHA, Vellenga E, Schuringa JJ.

Cancer Metab. 2019 Dec 27;7:11. doi: 10.1186/s40170-019-0206-y. eCollection 2019.


The acute myeloid leukemia associated AML1-ETO fusion protein alters the transcriptome and cellular progression in a single-oncogene expressing in vitro induced pluripotent stem cell based granulocyte differentiation model.

Tijchon E, Yi G, Mandoli A, Smits JGA, Ferrari F, Heuts BMH, Wijnen F, Kim B, Janssen-Megens EM, Schuringa JJ, Martens JHA.

PLoS One. 2019 Dec 23;14(12):e0226435. doi: 10.1371/journal.pone.0226435. eCollection 2019.


Protein quality control in the nucleolus safeguards recovery of epigenetic regulators after heat shock.

Azkanaz M, Rodríguez López A, de Boer B, Huiting W, Angrand PO, Vellenga E, Kampinga HH, Bergink S, Martens JH, Schuringa JJ, van den Boom V.

Elife. 2019 Jun 14;8. pii: e45205. doi: 10.7554/eLife.45205.


Elevated VMP1 expression in acute myeloid leukemia amplifies autophagy and is protective against venetoclax-induced apoptosis.

Folkerts H, Wierenga AT, van den Heuvel FA, Woldhuis RR, Kluit DS, Jaques J, Schuringa JJ, Vellenga E.

Cell Death Dis. 2019 May 29;10(6):421. doi: 10.1038/s41419-019-1648-4.


Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.

Hilberink J, Hazenberg C, van den Berg E, Mulder A, Schuringa JJ, van der Helm L, de Groot M, Choi G, de Bock GH, Vellenga E, Ammatuna E, Huls G.

Leuk Res. 2019 May;80:33-39. doi: 10.1016/j.leukres.2019.03.004. Epub 2019 Mar 18.


RUNX1 mutations enhance self-renewal and block granulocytic differentiation in human in vitro models and primary AMLs.

Gerritsen M, Yi G, Tijchon E, Kuster J, Schuringa JJ, Martens JHA, Vellenga E.

Blood Adv. 2019 Feb 12;3(3):320-332. doi: 10.1182/bloodadvances.2018024422.


Chromatin-Based Classification of Genetically Heterogeneous AMLs into Two Distinct Subtypes with Diverse Stemness Phenotypes.

Yi G, Wierenga ATJ, Petraglia F, Narang P, Janssen-Megens EM, Mandoli A, Merkel A, Berentsen K, Kim B, Matarese F, Singh AA, Habibi E, Prange KHM, Mulder AB, Jansen JH, Clarke L, Heath S, van der Reijden BA, Flicek P, Yaspo ML, Gut I, Bock C, Schuringa JJ, Altucci L, Vellenga E, Stunnenberg HG, Martens JHA.

Cell Rep. 2019 Jan 22;26(4):1059-1069.e6. doi: 10.1016/j.celrep.2018.12.098.


Copper deficiency-induced anemia is caused by a mitochondrial metabolic reprograming in erythropoietic cells.

Jensen EL, Gonzalez-Ibanez AM, Mendoza P, Ruiz LM, Riedel CA, Simon F, Schuringa JJ, Elorza AA.

Metallomics. 2019 Feb 20;11(2):282-290. doi: 10.1039/c8mt00224j.


Prospective Isolation and Characterization of Genetically and Functionally Distinct AML Subclones.

de Boer B, Prick J, Pruis MG, Keane P, Imperato MR, Jaques J, Brouwers-Vos AZ, Hogeling SM, Woolthuis CM, Nijk MT, Diepstra A, Wandinger S, Versele M, Attar RM, Cockerill PN, Huls G, Vellenga E, Mulder AB, Bonifer C, Schuringa JJ.

Cancer Cell. 2018 Oct 8;34(4):674-689.e8. doi: 10.1016/j.ccell.2018.08.014. Epub 2018 Sep 20.


BRD3/4 inhibition and FLT3-ligand deprivation target pathways that are essential for the survival of human MLL-AF9+ leukemic cells.

Carretta M, Brouwers-Vos AZ, Bosman M, Horton SJ, Martens JHA, Vellenga E, Schuringa JJ.

PLoS One. 2017 Dec 14;12(12):e0189102. doi: 10.1371/journal.pone.0189102. eCollection 2017.


Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.

Folkerts H, Hilgendorf S, Wierenga ATJ, Jaques J, Mulder AB, Coffer PJ, Schuringa JJ, Vellenga E.

Cell Death Dis. 2017 Jul 13;8(7):e2927. doi: 10.1038/cddis.2017.317.


Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models.

Carretta M, de Boer B, Jaques J, Antonelli A, Horton SJ, Yuan H, de Bruijn JD, Groen RWJ, Vellenga E, Schuringa JJ.

Exp Hematol. 2017 Jul;51:36-46. doi: 10.1016/j.exphem.2017.04.008. Epub 2017 Apr 26.


Smart niche usage: release its fat and burn it!

Schuringa JJ.

Blood. 2017 Mar 9;129(10):1239-1240. doi: 10.1182/blood-2017-01-761551. No abstract available.


Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches.

Antonelli A, Noort WA, Jaques J, de Boer B, de Jong-Korlaar R, Brouwers-Vos AZ, Lubbers-Aalders L, van Velzen JF, Bloem AC, Yuan H, de Bruijn JD, Ossenkoppele GJ, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Blood. 2016 Dec 22;128(25):2949-2959. doi: 10.1182/blood-2016-05-719021. Epub 2016 Oct 12.


Modeling of Chronic Myeloid Leukemia: An Overview of In Vivo Murine and Human Xenograft Models.

Sontakke P, Jaques J, Vellenga E, Schuringa JJ.

Stem Cells Int. 2016;2016:1625015. doi: 10.1155/2016/1625015. Epub 2016 Aug 25. Review.


Loss of ASXL1 triggers an apoptotic response in human hematopoietic stem and progenitor cells.

Hilgendorf S, Folkerts H, Schuringa JJ, Vellenga E.

Exp Hematol. 2016 Dec;44(12):1188-1196.e6. doi: 10.1016/j.exphem.2016.08.011. Epub 2016 Sep 8.


Modeling BCR-ABL and MLL-AF9 leukemia in a human bone marrow-like scaffold-based xenograft model.

Sontakke P, Carretta M, Jaques J, Brouwers-Vos AZ, Lubbers-Aalders L, Yuan H, de Bruijn JD, Martens AC, Vellenga E, Groen RW, Schuringa JJ.

Leukemia. 2016 Oct;30(10):2064-2073. doi: 10.1038/leu.2016.108. Epub 2016 Apr 29.


Hypoxia-Like Signatures Induced by BCR-ABL Potentially Alter the Glutamine Uptake for Maintaining Oxidative Phosphorylation.

Sontakke P, Koczula KM, Jaques J, Wierenga AT, Brouwers-Vos AZ, Pruis M, Günther UL, Vellenga E, Schuringa JJ.

PLoS One. 2016 Apr 7;11(4):e0153226. doi: 10.1371/journal.pone.0153226. eCollection 2016.


Autophagy Proteins ATG5 and ATG7 Are Essential for the Maintenance of Human CD34(+) Hematopoietic Stem-Progenitor Cells.

Gomez-Puerto MC, Folkerts H, Wierenga AT, Schepers K, Schuringa JJ, Coffer PJ, Vellenga E.

Stem Cells. 2016 Jun;34(6):1651-63. doi: 10.1002/stem.2347. Epub 2016 Mar 28.


Depletion of SAM50 Specifically Targets BCR-ABL-Expressing Leukemic Stem and Progenitor Cells by Interfering with Mitochondrial Functions.

Capala ME, Pruis M, Vellenga E, Schuringa JJ.

Stem Cells Dev. 2016 Mar 1;25(5):427-37. doi: 10.1089/scd.2015.0151. Epub 2016 Feb 8.


The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research.

Haematologica. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. Epub 2016 Jan 27.


Non-canonical PRC1.1 Targets Active Genes Independent of H3K27me3 and Is Essential for Leukemogenesis.

van den Boom V, Maat H, Geugien M, Rodríguez López A, Sotoca AM, Jaques J, Brouwers-Vos AZ, Fusetti F, Groen RW, Yuan H, Martens AC, Stunnenberg HG, Vellenga E, Martens JH, Schuringa JJ.

Cell Rep. 2016 Jan 12;14(2):332-46. doi: 10.1016/j.celrep.2015.12.034. Epub 2015 Dec 31.


Constitutive NF-κB activation in AML: Causes and treatment strategies.

Bosman MC, Schuringa JJ, Vellenga E.

Crit Rev Oncol Hematol. 2016 Feb;98:35-44. doi: 10.1016/j.critrevonc.2015.10.001. Epub 2015 Oct 18. Review.


Mitochondrial Dysfunction in Human Leukemic Stem/Progenitor Cells upon Loss of RAC2.

Capala ME, Maat H, Bonardi F, van den Boom V, Kuipers J, Vellenga E, Giepmans BN, Schuringa JJ.

PLoS One. 2015 May 27;10(5):e0128585. doi: 10.1371/journal.pone.0128585. eCollection 2015.


Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib.

van der Helm LH, Bosman MC, Schuringa JJ, Vellenga E.

Br J Haematol. 2015 Nov;171(4):652-5. doi: 10.1111/bjh.13418. Epub 2015 Apr 14. No abstract available.


ELMO1 is upregulated in AML CD34+ stem/progenitor cells, mediates chemotaxis and predicts poor prognosis in normal karyotype AML.

Capala ME, Vellenga E, Schuringa JJ.

PLoS One. 2014 Oct 31;9(10):e111568. doi: 10.1371/journal.pone.0111568. eCollection 2014.


The TAK1-NF-κB axis as therapeutic target for AML.

Bosman MC, Schepers H, Jaques J, Brouwers-Vos AZ, Quax WJ, Schuringa JJ, Vellenga E.

Blood. 2014 Nov 13;124(20):3130-40. doi: 10.1182/blood-2014-04-569780. Epub 2014 Oct 6.


CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia.

Korthuis PM, Berger G, Bakker B, Rozenveld-Geugien M, Jaques J, de Haan G, Schuringa JJ, Vellenga E, Schepers H.

Leukemia. 2015 Mar;29(3):625-35. doi: 10.1038/leu.2014.259. Epub 2014 Sep 3.


Ex vivo assays to study self-renewal, long-term expansion, and leukemic transformation of genetically modified human hematopoietic and patient-derived leukemic stem cells.

Sontakke P, Carretta M, Capala M, Schepers H, Schuringa JJ.

Methods Mol Biol. 2014;1185:195-210. doi: 10.1007/978-1-4939-1133-2_13.


Convergence of hypoxia and TGFβ pathways on cell cycle regulation in human hematopoietic stem/progenitor cells.

Wierenga AT, Vellenga E, Schuringa JJ.

PLoS One. 2014 Mar 31;9(3):e93494. doi: 10.1371/journal.pone.0093494. eCollection 2014.


Aging impairs long-term hematopoietic regeneration after autologous stem cell transplantation.

Woolthuis CM, Mariani N, Verkaik-Schakel RN, Brouwers-Vos AZ, Schuringa JJ, Vellenga E, de Wolf JT, Huls G.

Biol Blood Marrow Transplant. 2014 Jun;20(6):865-71. doi: 10.1016/j.bbmt.2014.03.001. Epub 2014 Mar 7.


Loss of quiescence and impaired function of CD34(+)/CD38(low) cells one year following autologous stem cell transplantation.

Woolthuis CM, Brouwers-Vos AZ, Huls G, de Wolf JT, Schuringa JJ, Vellenga E.

Haematologica. 2013 Dec;98(12):1964-71. doi: 10.3324/haematol.2013.086744. Epub 2013 Sep 13.


A single center analysis of nucleophosmin in acute myeloid leukemia: value of combining immunohistochemistry with molecular mutation analysis.

Woolthuis CM, Mulder AB, Verkaik-Schakel RN, Rosati S, Diepstra A, van den Berg E, Schuringa JJ, Vellenga E, Kluin PM, Huls G.

Haematologica. 2013 Oct;98(10):1532-8. doi: 10.3324/haematol.2012.079806. Epub 2013 May 28.


Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.

Bosman MC, Schuringa JJ, Quax WJ, Vellenga E.

Exp Hematol. 2013 Jun;41(6):530-538.e1. doi: 10.1016/j.exphem.2013.02.002. Epub 2013 Feb 13.


The AAA+ ATPase RUVBL2 is a critical mediator of MLL-AF9 oncogenesis.

Osaki H, Walf-Vorderwülbecke V, Mangolini M, Zhao L, Horton SJ, Morrone G, Schuringa JJ, de Boer J, Williams O.

Leukemia. 2013 Jul;27(7):1461-8. doi: 10.1038/leu.2013.42. Epub 2013 Feb 13.


Impaired long-term expansion and self-renewal potential of pediatric acute myeloid leukemia-initiating cells by PTK787/ZK 222584.

Weidenaar AC, Ter Elst A, Kampen KR, Meeuwsen-de Boer T, Kamps WA, Schuringa JJ, de Bont ES.

Mol Cancer Res. 2013 Apr;11(4):339-48. doi: 10.1158/1541-7786.MCR-12-0113. Epub 2013 Feb 7.


Nonredundant and locus-specific gene repression functions of PRC1 paralog family members in human hematopoietic stem/progenitor cells.

van den Boom V, Rozenveld-Geugien M, Bonardi F, Malanga D, van Gosliga D, Heijink AM, Viglietto G, Morrone G, Fusetti F, Vellenga E, Schuringa JJ.

Blood. 2013 Mar 28;121(13):2452-61. doi: 10.1182/blood-2012-08-451666. Epub 2013 Jan 24.


A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers.

Bonardi F, Fusetti F, Deelen P, van Gosliga D, Vellenga E, Schuringa JJ.

Mol Cell Proteomics. 2013 Mar;12(3):626-37. doi: 10.1074/mcp.M112.021931. Epub 2012 Dec 11.


MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny.

Horton SJ, Jaques J, Woolthuis C, van Dijk J, Mesuraca M, Huls G, Morrone G, Vellenga E, Schuringa JJ.

Leukemia. 2013 Apr;27(5):1116-26. doi: 10.1038/leu.2012.343. Epub 2012 Nov 26.


Cancer stem cell definitions and terminology: the devil is in the details.

Valent P, Bonnet D, De Maria R, Lapidot T, Copland M, Melo JV, Chomienne C, Ishikawa F, Schuringa JJ, Stassi G, Huntly B, Herrmann H, Soulier J, Roesch A, Schuurhuis GJ, Wöhrer S, Arock M, Zuber J, Cerny-Reiterer S, Johnsen HE, Andreeff M, Eaves C.

Nat Rev Cancer. 2012 Nov;12(11):767-75. doi: 10.1038/nrc3368. Epub 2012 Oct 11. Review.


Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma.

Groen RW, Noort WA, Raymakers RA, Prins HJ, Aalders L, Hofhuis FM, Moerer P, van Velzen JF, Bloem AC, van Kessel B, Rozemuller H, van Binsbergen E, Buijs A, Yuan H, de Bruijn JD, de Weers M, Parren PW, Schuringa JJ, Lokhorst HM, Mutis T, Martens AC.

Blood. 2012 Jul 19;120(3):e9-e16. doi: 10.1182/blood-2012-03-414920. Epub 2012 May 31.


STAT5-mediated self-renewal of normal hematopoietic and leukemic stem cells.

Schepers H, Wierenga AT, Vellenga E, Schuringa JJ.

JAKSTAT. 2012 Jan 1;1(1):13-22. doi: 10.4161/jkst.19316. Review.


Genetic and epigenetic alterations that drive leukemic stem cell self-renewal.

van den Boom V, Horton SJ, Schuringa JJ.

J Stem Cells. 2012;7(3):155-79. doi: jsc.2012.7.3.155. Review.


Treatment with high-dose simvastatin inhibits geranylgeranylation in AML blast cells in a subset of AML patients.

van der Weide K, de Jonge-Peeters S, Huls G, Fehrmann RS, Schuringa JJ, Kuipers F, de Vries EG, Vellenga E.

Exp Hematol. 2012 Mar;40(3):177-186.e6. doi: 10.1016/j.exphem.2011.11.008. Epub 2011 Nov 25.


Downregulation of MEIS1 impairs long-term expansion of CD34+ NPM1-mutated acute myeloid leukemia cells.

Woolthuis CM, Han L, Verkaik-Schakel RN, van Gosliga D, Kluin PM, Vellenga E, Schuringa JJ, Huls G.

Leukemia. 2012 Apr;26(4):848-53. doi: 10.1038/leu.2011.277. Epub 2011 Oct 11. No abstract available.


Gene expression profiling in the leukemic stem cell-enriched CD34+ fraction identifies target genes that predict prognosis in normal karyotype AML.

de Jonge HJ, Woolthuis CM, Vos AZ, Mulder A, van den Berg E, Kluin PM, van der Weide K, de Bont ES, Huls G, Vellenga E, Schuringa JJ.

Leukemia. 2011 Dec;25(12):1825-33. doi: 10.1038/leu.2011.172. Epub 2011 Jul 15.


Treatment strategies in acute myeloid leukemia.

Han LN, Zhou J, Schuringa JJ, Vellenga E.

Chin Med J (Engl). 2011 May;124(9):1409-21. Review.


Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD.

de Jonge HJ, Valk PJ, de Bont ES, Schuringa JJ, Ossenkoppele G, Vellenga E, Huls G.

Haematologica. 2011 Sep;96(9):1310-7. doi: 10.3324/haematol.2011.040592. Epub 2011 May 23.


Zinc finger protein 521 antagonizes early B-cell factor 1 and modulates the B-lymphoid differentiation of primary hematopoietic progenitors.

Mega T, Lupia M, Amodio N, Horton SJ, Mesuraca M, Pelaggi D, Agosti V, Grieco M, Chiarella E, Spina R, Moore MA, Schuringa JJ, Bond HM, Morrone G.

Cell Cycle. 2011 Jul 1;10(13):2129-39. Epub 2011 Jul 1.


Supplemental Content

Loading ...
Support Center